Sinopharm Group Co., Ltd. (hereinafter referred to as "Sinopharm Group") is the carrier of Sinopharm Group's pharmaceutical trade and distribution sector. The company was established in Shanghai in January 2003 and listed in Hong Kong in September 1 (2009.HK). It has more than 9 branches and subsidiaries, including two A-share listed companies, Sinopharm Group Medicine Co., Ltd. (Sinopharm Group, 01099.SH) and Sinopharm Group Accord Medicines Co., Ltd. (Sinopharm Accord, 1100.SZ), with a total of about 600511 employees.
Under the correct leadership of Sinopharm Group, the company's board of directors and party committee, Sinopharm Holdings has continuously deepened mixed-ownership reform, continued to promote integrated development, vigorously implemented scientific and technological innovation, and embarked on a development path of joint restructuring, capital operation, resource integration, and integrated innovation. It has now developed into a leading distributor and retailer of Chinese pharmaceuticals, healthcare products, and medical devices, as well as a leading supply chain service provider.
In 2021, Sinopharm Group achieved business revenue of RMB 5210.51 billion (the same below), a year-on-year increase of 14.16%. Among them, the revenue of drug distribution business was RMB 3899.55 billion. The terminal network covers about 60 stores in various provinces (autonomous regions and municipalities). The medical device business developed rapidly, with sales revenue of RMB 1081.29 billion. The drug retail network was improved and optimized, and the total number of stores including social pharmacies, professional pharmacies, and "dual-channel" pharmacies exceeded 10000, with business revenue increasing by 20.26% year-on-year.
Sinopharm Holdings has thoroughly implemented the decisions and deployments of the CPC Central Committee and the State Council on improving the modernization level of the industrial chain and supply chain and maintaining the security and stability of the industrial chain and supply chain. It was rated as a "National Supply Chain Innovation and Application Demonstration Enterprise in 8" by the Ministry of Commerce and eight other units.
凭借良好的经营业绩和公司治理水平，国药控股位列2022年《财富》中国500强第24位、医药企业第一位。2022年国药控股环境、社会及管治（“ESG”）在MSCI（明晟）的评级结果提升为A级，并入选央企ESG治理先锋50指数。位列2022年中国上市公司品牌价值100强第28位，成为中国上市医药企业品牌价值的佼佼者。
